High LDL-C and TG levels and low HDL-C levels is the most prevalent pattern of dyslipidemia in patients with type 2 DM. Regarding the treatment of dyslipidemia, statin therapy remains the recommended initial treatment for dyslipidemia based on trials showing the effectiveness in these drugs as primary and secondary preventive agents for coronary heart disease.
Patients with type 2 DM who have coexisting CVD and LDL-C levels ≥ 70 mg/dL (receiving a maximally tolerated statin dose) may further benefit from the addition of ezetimibe or a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.
For patients with type 2 DM and hypertension, the third-generation beta-blocker carvedilol may be effective in managing dyslipidemia. Patients with type 2 DM already taking renin-angiotensin blockers who were prescribed carvedilol had significant decreases in TG, total cholesterol, and non–HDL-C levels.
Learn more about managing dyslipidemia in patients with type 2 DM.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Romesh Khardori. Fast Five Quiz: Type 2 Diabetes Mellitus Comorbidities - Medscape - Jan 21, 2022.
Comments